The nation is facing competing public health issues: the need to treat a large number of Americans with acute and chronic pain vs the crisis of prescription opioid abuse. Pri-Med’s Strategies for Effective Pain Management in Clinical Practice curriculum focuses on improving practitioners’ ability to recognize, diagnose, and classify pain; educating clinicians on the full spectrum of pain management options, including nonopioid pharmacologic interventions; and providing risk reduction strategies through integration of opioids into individualized pain management plans. Clinicians will learn to recognize signs and symptoms of opioid dependence and abuse in order to optimally manage patients’ pain and medication use.

This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).

Charles E. Argoff, MD, FABPM

Professor of Neurology, Albany Medical College, Director, Comprehensive Pain Center, Albany Medical Center, Albany, NY

Oscar A. de Leon-Casasola, MD

Professor of Anesthesiology and Medicine, Senior Vice-Chair, The Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, Chief, Pain Medicine and Professor of Oncology, Roswell Park Cancer Institute, Buffalo, NY

Katherine E. Galluzzi, DO, CMD, FACOFP

FACOFP, Professor and Chair, Department of Geriatrics, Philadelphia College of Osteopathic Medicine, Philadelphia, PAs

Supported by Opioid Analgesic REMS Program Companies

More than half of patients with type 2 diabetes are obese. Modest and sustained weight loss has been shown to improve glycemic control and reduce the need for glucose-lowering medications in patients with type 2 diabetes who are obese. Despite the proven benefits of weight loss, most patients remain on therapeutic regimens that focus solely on lowering A1c. This program will provide evidence-based strategies for managing both glycemic and metabolic outcomes and explore the role of the incretin hormones GLP-1 and GIP in the treatment of type 2 diabetes and its metabolic comorbidities.  

Silvio E. Inzucchi, MD

Professor of Medicine, Clinical Chief, Endocrinology, Medical Director, Yale Diabetes Center, Yale School of Medicine, Yale-New Haven Hospital, New Haven, CT

Anne Peters, MD

Professor of Clinical Medicine, Keck School of Medicine of USC, Los Angeles, CA

Supported by Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Session Overview to Come 

Ty J. Gluckman, MD, FACC, FAHA

Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS), Providence Heart Institute, Providence St. Joseph Health, Portland, OR

One in fifty people in the U.S. has an unruptured brain aneurysm, and one ruptures every 18 minutes. Despite low frequency, brain aneurysms are high in mortality, because the lack of a timely diagnosis often leads to death. Complicating matters more, many of the symptoms are associated with other less dangerous conditions, such as influenza or stress. This session will describe the importance of early detection, since brain aneurysms are treatable via proper identification, and will highlight risk factors and populations who are most vulnerable. Faculty will also review treatment options for clinicians to recognize or use in practice. 

Christopher S. Ogilvy, MD

Director, Endovascular and Operative Neurovascular Surgery, BIDMC Brain Aneurysm Institute, Professor of Neurosurgery, Harvard Medical School, Boston, MA